肺动脉高压
甲基化
RNA甲基化
核糖核酸
医学
内科学
癌症研究
生物
甲基转移酶
遗传学
基因
作者
Yu Xiao,Yanyan Zhang,Jie Huang,Bing Cheng,Yuwu Jiang,Zengxian Sun,Yun Liu
出处
期刊:Pharmacology
[S. Karger AG]
日期:2023-01-01
卷期号:108 (6): 497-503
摘要
<b><i>Background:</i></b> The most prevalent kind of RNA methylation modification existing in eukaryotes is N6-methyladenosine (m6A), which is a reversible type of posttranscriptional modification. <b><i>Summary:</i></b> Many studies have reported that m6A participates in cell differentiation, self-renewal, invasion, and apoptosis by modifying protein synthesis. Furthermore, m6A modification is also involved in disease progression and pulmonary vascular remodeling in pulmonary hypertension. However, very few researchers have investigated the effect of m6A modifications on pulmonary hypertension. <b><i>Key Messages:</i></b> Here, we have reviewed the latest research advances in the field of m6A RNA methylation in pulmonary hypertension and explored its regulatory role in pulmonary hypertension development and progression.
科研通智能强力驱动
Strongly Powered by AbleSci AI